SCHEMBL24124873

SCHEMBL24124873

CN(Cc1ccc(NC(=O)OC(C)(C)C)cc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 1/20 0.50
▸ HDAC3 O15379 1/20 0.48
▸ HDAC1 Q13547 1/20 0.48
▸ HDAC2 Q92769 1/20 0.48
▸ NCOR2 Q9Y618 1/20 0.48
▸ AKT1 P31749 2/20 0.48
▸ DRD2 P14416 1/20 0.47
▸ GLS O94925 1/20 0.47
▸ BCHE P06276 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ CTSL P07711 2/20 0.46
▸ CTSB P07858 2/20 0.46
▸ CTSS P25774 2/20 0.46
▸ PTGDR2 Q9Y5Y4 1/20 0.45
▸ CRHBP P24387 1/20 0.45
▸ CRHR2 Q13324 1/20 0.45
▸ NAMPT P43490 2/20 0.45
▸ MMP1 P03956 1/20 0.44
▸ MMP2 P08253 1/20 0.44
▸ MMP9 P14780 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22930812 0.83 CYP17A1 (0.57) CYP17A1HDAC3NCOR2AKT1DRD2
SCHEMBL4326881 0.81 CTSL (0.51) CYP17A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7042995 0.80 DRD2 (0.59) CYP17A1AKT1DRD2GLSCTSS
SCHEMBL10249437 0.80 CYP17A1 (0.68) CYP17A1AKT1DRD2GLSPTGDR2
SCHEMBL30270537 0.80 AKT1 (0.47) CYP17A1AKT1DRD2GLSCTSL
SCHEMBL13304138 0.79 MAPT (0.54) CYP17A1DRD2PTGDR2NAMPTKDM4E
SCHEMBL28056138 0.79 CA2 (0.54) CYP17A1AKT1DRD2GLSNAMPT
SCHEMBL30872826 0.78 CYP17A1 (0.52) CYP17A1HDAC3NCOR2AKT1DRD2
SCHEMBL1854209 0.78 ATM (0.56) CYP17A1AKT1DRD2GLSPTGDR2
SCHEMBL25924692 0.78 HDAC1 (0.66) HDAC3HDAC1HDAC2NCOR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
EP-4164622-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA Icahn School of Medicine at Mount Sinai (US) 2023-04-19 — — EP disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 CYP17A1 1516/4885HDAC3 1997/4885HDAC1 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback